Inflammatory Bowel Disease (IBD) is an enigmatic group of chronic disorders that affect millions of individuals worldwide. It can occur in both children and adults and is characterized by chronic inflammation in the digestive tract, leading to significant disruptions in daily life. The prevalence of IBD has been progressively increasing in recent decades, with estimates suggesting that it affects a significant number of people globally, including approximately 3 million males and 3.9 million females. In the United States alone, there are 1.6 million diagnosed cases, with most individuals being diagnosed before the age of 35[1].
Inflammatory bowel disease(IBD)[1]
Recently, GemPharmatech organized a themed lecture focusing on the latest breakthroughs in IBD research and animal models. Our presentation provided a comprehensive summary of the underlying mechanisms of IBD, current treatment approaches, cutting-edge research trends, and the potential solutions offered by animal models.
To enhance the understanding of IBD, we have compiled some frequently asked questions from our presentation.
Q1: What animal models are available to evaluate the efficacy of antibody drugs for IBD?
Q2: When it comes to treating IBD, how should we regard the use of microbial preparations?
Q3: What are the differences between the IL-10 KO mouse model and the DSS/DNBS colitis models?
Q4: Which model, acute or chronic colitis, better simulates IBD?
To learn more about how to address common concerns and provide clarity on various aspects of IBD, read this article here: https://en.gempharmatech.com/content/details100032_4155621.html
